Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Dec 23;111(51):18100-1.
doi: 10.1073/pnas.1420596111. Epub 2014 Dec 15.

Targeting osteosarcoma

Darien E Reed  1 , Kevan M Shokat  2
Affiliations
Comment

Targeting osteosarcoma

Darien E Reed et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: K.M.S. is a consultant to Takeda Pharmaceuticals, which is conducting MLN0128 clinical trials. K.M.S. is also an inventor on patents related to MLN0128 held by the University of California, San Francisco, and sublicensed to Takeda Pharmaceuticals.

Comment on

  • Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
    Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, Ambrogio L, Sougnez C, Sivachenko A, Walensky LD, Wagle N, Mora J, de Torres C, Lavarino C, Dos Santos Aguiar S, Yunes JA, Brandalise SR, Mercado-Celis GE, Melendez-Zajgla J, Cárdenas-Cardós R, Velasco-Hidalgo L, Roberts CW, Garraway LA, Rodriguez-Galindo C, Gabriel SB, Lander ES, Golub TR, Orkin SH, Getz G, Janeway KA. Perry JA, et al. Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5564-73. doi: 10.1073/pnas.1419260111. Epub 2014 Dec 15. Proc Natl Acad Sci U S A. 2014. PMID: 25512523 Free PMC article.

References

    1. Perry JA, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA. 2014;111:E5564–E5573. - PMC - PubMed
    1. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—Where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–532. - PubMed
    1. Chen X, et al. St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Reports. 2014;7(1):104–112. - PMC - PubMed
    1. Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. - PMC - PubMed
    1. McIntyre JF, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994;12(5):925–930. - PubMed

MeSH terms

Substances

LinkOut - more resources